Latest News and Press Releases

Robbins LLP is Investigating Allegations that James Hardie Industries plc (JHX) Mislead Investors Regarding Inventory Destocking

A class action alleges MoonLake misled investors about SLK’s Nanobody advantages over BIMZELX. Phase 3 results showed no superiority, sending shares down 8

Quanex’s stock fell 23% after revelations that its Mexico facility was underinvested, equipment degraded, and prior statements were misleading.

KBR’s stock fell after revelations that it misled investors about HomeSafe’s troubled DoD contract, which was later terminated due to ongoing performance.

Cytokinetic stock fell after revelations it misled investors about aficamten’s FDA approval timeline and failed to disclose risks delaying the NDA process

Jasper’s stock fell 55% after disclosures that it lacked adequate controls over third-party manufacturers, misstating its compliance and operations.

Robbins LLP is Investigating Allegations that MoonLake Immunotherapeutics (MLTX) Mislead Investors Regarding the Efficacy of its Drug Candidate

Robbins LLP is Investigating Allegations that aTyr Pharma, Inc. (ATYR) Mislead Investors Regarding the Efficacy of its Drug Candidate

Robbins LLP is Investigating Allegations that Marex Group PLC (MRX) Mislead Investors Regarding its Revenue Projections

Robbins LLP is Investigating Allegations that Cepton, Inc. (CPTN) Misled Investors in Connection with the Company's Acquisition by Koito Manufacturing Co.,